Coya Therapeutics (NASDAQ:COYA) Stock Price Expected to Rise, BTIG Research Analyst Says

Coya Therapeutics (NASDAQ:COYA) had its price objective lifted by BTIG Research from $15.00 to $16.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 169.59% from the stock’s current price.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th. Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Wednesday, September 17th. Lake Street Capital restated a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, October 8th. Finally, D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a report on Wednesday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Trading Down 2.5%

Shares of COYA traded down $0.16 during trading hours on Thursday, hitting $5.94. The company had a trading volume of 117,075 shares, compared to its average volume of 100,744. The company has a market capitalization of $99.35 million, a PE ratio of -4.79 and a beta of 0.20. Coya Therapeutics has a one year low of $4.65 and a one year high of $8.29. The company’s fifty day moving average price is $6.10 and its two-hundred day moving average price is $6.05.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.78 million. Analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Trading of Coya Therapeutics

A number of hedge funds have recently modified their holdings of COYA. CM Management LLC raised its position in Coya Therapeutics by 50.0% during the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after acquiring an additional 100,000 shares in the last quarter. Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics during the 1st quarter worth approximately $1,083,000. Jane Street Group LLC lifted its stake in shares of Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Coya Therapeutics during the second quarter worth $119,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Coya Therapeutics during the first quarter worth $65,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.